- Abstracts highlight SonoThera’s novel, ultrasound-guided nonviral gene therapy platform’s ability to non-invasively deliver nucleic acid payloads of diverse formats and sizes to targeted organs and tissues.
- ASGCT presentations highlight targeted DNA delivery to the kidney and liver resulting in durable gene expression, the ability to re-dose and dose titrate with exemplary safety and efficacy.
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced that it will present four abstracts at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place in Baltimore, Maryland, May 7-11, 2024.
All four presentations feature SonoThera’s ultrasound-guided nonviral gene therapy platform, which is being developed to non-invasively deliver nucleic acid payloads of diverse formats and sizes. While the platform is designed to selectively target a wide range of organs within the body, research presented at ASCGT focuses on the targeted delivery of redosable and therapeutically relevant DNA payloads that result in robust and durable gene expression in the kidney and liver in murine and NHP models.
“We are pleased to share our recent research further advancing our technology,” said Kenneth Greenberg, PhD, CEO of SonoThera. “Our scientific team’s innovation demonstrates our commitment to realizing the enormous potential of ultrasound as an effective, nonviral delivery method which may solve some of today’s biggest challenges in genetic medicine. We look forward to presenting these results at ASGCT.”
Poster Presentation Details:
Title: Kidney-targeted non-viral gene delivery using a novel noninvasive transcutaneous ultrasound delivery platform enables redosable, titratable, and durable gene expression in healthy mice and NHPs, and polycystic kidneys mouse model.
Presenter: Bert Frederich, PhD
Session Date/Time: Friday, May 10, 12:00pm - 1:30pm, Exhibit Hall
Abstract Number: 1740
Title: Targeted non-viral gene delivery through transcutaneous ultrasound enables rapid, robust, redosable, titratable, and durable gene expression in the liver in murine and NHP models.
Presenter: Surabhi Rao, MSc
Session Date/Time: Thursday, May 9, 12:00pm - 1:30pm, Exhibit Hall
Abstract Number: 1228
Title: Cellular phenotyping of non-human primate and mouse kidney and liver following a novel targeted transcutaneous ultrasound-mediated gene delivery demonstrates gene expression in clinically relevant cell types.
Presenter: Katie Benthall, PhD
Session Date/Time: Friday, May 10, 12:00pm - 1:30pm, Exhibit Hall
Abstract Number: 1735
Title: Development of a next-generation non-viral human FVIII therapeutic administered through targeted transcutaneous ultrasound enables normal physiological levels of FVIII transgene expression in a redosable and titratable manner.
Presenter: Margot Krivega, PhD
Session Date/Time: Thursday, May 9, 12:00pm - 1:30pm, Exhibit Hall
Abstract Number: 1229
About SonoThera™
Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera, Inc. is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. SonoThera is headquartered in South San Francisco, California. Visit www.sonothera.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430291799/en/
Contacts
Investor Inquiries:
investors@sonothera.com
Media Inquiries:
Mog & Springer Communications on behalf of SonoThera, Inc.
Elizabeth Harness, Principal, P: +1 585-435-7379, elizabeth.harness@mogandspringer.com
